PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer

Exclusion Criteria

• •Pts w epithelial ovarian tumors of low malignant potential (borderline tumor)
• •Pts w history of other invasive malignancies, w exception of non-melanoma skin cancer, are excluded if there is any evidence of other malignancy being present within last 5 yrs
• •Pts who have following cardiac conditions: uncontrolled angina or myocardial infarction within past 6 months; diagnosed or suspected congenital long QT syndrome; Any history of clinically significant ventricular arrhythmias; Prolonged QTc interval on pre-entry electrocardiogram on both Fridericia \& Bazett's correction; uncontrolled hypertension
• •History of significant bleeding disorder unrelated to cancer, including: diagnosed congenital bleeding disorders; diagnosed acquired bleeding disorder within 1 yr
• •Pts currently taking drugs that are generally accepted to have risk of causing Torsades de Pointes including: quinidine, procainamide, disopyramide; amiodarone, sotalol, ibutilide, dofetilide; erythromycins, clarithromycin; chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide; cisapride, bepridil, droperidol, methadone, arsenic, chloroquine, domperidone, halofantrine, levomethadyl, pentamidine, sparfloxacin, lidoflazine
• •Serum creatinine \> 1.5 times institutional upper limits of normal
• •Pts taking certain concomitant medications, consider following prohibitions: medications that inhibit platelet function or anticoagulants
• •Pts who have received radiation therapy to \> 30 percent of bone marrow
• •Pts w history of grade 3 hypersensitivity to paclitaxel or carboplatin
• •Pts w septicemia, severe infection, acute hepatitis, other uncontrolled severe medical conditions